Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

被引：71

作者：

Abdel-Rahman, Omar ^{[1
]}

ElHalawani, Hesham ^{[1
]}

Fouad, Mona ^{[2
]}

机构：

[1] Ain Shams Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[2] Ain Shams Univ, Fac Med, Dept Med Microbiol & Immunol, Cairo, Egypt

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 11期

关键词：

colitis; diarrhea; ipilimumab; nivolumab; DOUBLE-BLIND; METASTATIC MELANOMA; ANTI-CTLA4; ANTIBODY; ADVERSE EVENTS; OPEN-LABEL; IPILIMUMAB; NIVOLUMAB; SAFETY; TOXICITIES; BLOCKADE;

D O I：

10.2217/imt.15.87

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim: We performed a meta-analysis of the risk of selected gastrointestinal toxicities associated with immune checkpoint inhibitors. Patients & methods: Eligible studies included randomized trials of patients with solid tumors on ipilimumab, nivolumab, pembrolizumab, tremelimumab, pidilizumab and atezolizumab, describing events of diarrhea, vomiting or colitis. Results: After exclusion of ineligible studies, a total of ten clinical trials were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea, vomiting and colitis was 1.64 (95% CI: 1.19-2.26; p = 0.002), 0.72 (95% CI: 0.49-1.07; p = 0.1), 10.35 (95% CI: 5.78-18.53; p < 0.00001), respectively. Conclusion: Our meta-analysis has demonstrated that immune checkpoint inhibitors are associated with a significantly increased risk of all grade and high-grade colitis.

引用

页码：1213 / 1227

页数：15

共 51 条

[41] Nivolumab in Previously Untreated Melanoma without BRAF Mutation [J].

Robert, Caroline ;

Long, Georgina V. ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Maio, Michele ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Arance, Ana ;

Schmidt, Henrik ;

Schadendorf, Dirk ;

Gogas, Helen ;

Lundgren-Eriksson, Lotta ;

Horak, Christine ;

Sharkey, Brian ;

Waxman, Ian M. ;

Atkinson, Victoria ;

Ascierto, Paolo A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :320-330

[42] Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [J].

Robert, Caroline ;

Thomas, Luc ;

Bondarenko, Igor ;

O'Day, Steven ;

Weber, Jeffrey ;

Garbe, Claus ;

Lebbe, Celeste ;

Baurain, Jean-Francois ;

Testori, Alessandro ;

Grob, Jean-Jacques ;

Davidson, Neville ;

Richards, Jon ;

Maio, Michele ;

Hauschild, Axel ;

Miller, Wilson H., Jr. ;

Gascon, Pere ;

Lotem, Michal ;

Harmankaya, Kaan ;

Ibrahim, Ramy ;

Francis, Stephen ;

Chen, Tai-Tsang ;

Humphrey, Rachel ;

Hoos, Axel ;

Wolchok, Jedd D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2517-2526

[43]

Slangen Rob Me, 2013, World J Gastrointest Pharmacol Ther, V4, P80, DOI 10.4292/wjgpt.v4.i3.80

[44] LOSS OF CTLA-4 LEADS TO MASSIVE LYMPHOPROLIFERATION AND FATAL MULTIORGAN TISSUE DESTRUCTION, REVEALING A CRITICAL NEGATIVE REGULATORY ROLE OF CTLA-4 [J].

TIVOL, EA ;

BORRIELLO, F ;

SCHWEITZER, AN ;

LYNCH, WP ;

BLUESTONE, JA ;

SHARPE, AH .

IMMUNITY, 1995, 3 (05) :541-547

[45] Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [J].

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Brahmer, Julie R. ;

Gettinger, Scott N. ;

Smith, David C. ;

McDermott, David F. ;

Powderly, John D. ;

Carvajal, Richard D. ;

Sosman, Jeffrey A. ;

Atkins, Michael B. ;

Leming, Philip D. ;

Spigel, David R. ;

Antonia, Scott J. ;

Horn, Leora ;

Drake, Charles G. ;

Pardoll, Drew M. ;

Chen, Lieping ;

Sharfman, William H. ;

Anders, Robert A. ;

Taube, Janis M. ;

McMiller, Tracee L. ;

Xu, Haiying ;

Korman, Alan J. ;

Jure-Kunkel, Maria ;

Agrawal, Shruti ;

McDonald, Daniel ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Wigginton, Jon M. ;

Sznol, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2443-2454

[46] LYMPHOPROLIFERATIVE DISORDERS WITH EARLY LETHALITY IN MICE DEFICIENT IN CTLA-4 [J].

WATERHOUSE, P ;

PENNINGER, JM ;

TIMMS, E ;

WAKEHAM, A ;

SHAHINIAN, A ;

LEE, KP ;

THOMPSON, CB ;

GRIESSER, H ;

MAK, TW .

SCIENCE, 1995, 270 (5238) :985-988

[47] Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J].

Weber, Jeffrey S. ;

D'Angelo, Sandra P. ;

Minor, David ;

Hodi, F. Stephen ;

Gutzmer, Ralf ;

Neyns, Bart ;

Hoeller, Christoph ;

Khushalani, Nikhil I. ;

Miller, Wilson H., Jr. ;

Lao, Christopher D. ;

Linette, Gerald P. ;

Thomas, Luc ;

Lorigan, Paul ;

Grossmann, Kenneth F. ;

Hassel, Jessica C. ;

Maio, Michele ;

Sznol, Mario ;

Ascierto, Paolo A. ;

Mohr, Peter ;

Chmielowski, Bartosz ;

Bryce, Alan ;

Svane, Inge M. ;

Grob, Jean-Jacques ;

Krackhardt, Angela M. ;

Horak, Christine ;

Lambert, Alexandre ;

Yang, Arvin S. ;

Larkin, James .

LANCET ONCOLOGY, 2015, 16 (04) :375-384

[48] Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab [J].

Weber, Jeffrey S. ;

Kaehler, Katharina C. ;

Hauschild, Axel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2691-2697

[49] Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial [J].

Westin, Jason R. ;

Chu, Fuliang ;

Zhang, Min ;

Fayad, Luis E. ;

Kwak, Larry W. ;

Fowler, Nathan ;

Romaguera, Jorge ;

Hagemeister, Fredrick ;

Fanale, Michelle ;

Samaniego, Felipe ;

Feng, Lei ;

Baladandayuthapani, Veerabhadran ;

Wang, Zhiqiang ;

Ma, Wencai ;

Gao, Yanli ;

Wallace, Michael ;

Vence, Luis M. ;

Radvanyi, Laszlo ;

Muzzafar, Tariq ;

Rotem-Yehudar, Rinat ;

Davis, R. Eric ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2014, 15 (01) :69-77

[50] Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study [J].

Wolchok, Jedd D. ;

Neyns, Bart ;

Linette, Gerald ;

Negrier, Sylvie ;

Lutzky, Jose ;

Thomas, Luc ;

Waterfield, William ;

Schadendorf, Dirk ;

Smylie, Michael ;

Guthrie, Troy, Jr. ;

Grob, Jean-Jacques ;

Chesney, Jason ;

Chin, Kevin ;

Chen, Kun ;

Hoos, Axel ;

O'Day, Steven J. ;

Lebbe, Celeste .

LANCET ONCOLOGY, 2010, 11 (02) :155-164

← 1 2 3 4 5 6 →